Medicovestor, Inc. Announces Issuance/Approval of 3 Patents by the USPTO Medicovestor secures 3 USPTO patents, advancing its innovative ADC platform and unique antibodies for enhanced cancer treatment and autoimmune potential.

Medicovestor Selected as Finalist to Present Its First-in-Class ADC Platforms at JP Morgan Asset Management: Life Sciences Innovation Summit Medicovestor named finalist for JP Morgan Asset Management: Life Sciences Innovation Summit, showcasing pioneering ADC platforms on May 14th – 15th, 2024.

Medicovestor, Inc announces the completion of an oversubscribed Seed Financing round to advance its novel Antibody Drug-Conjugate (ADC) platforms Medicovestor excels in oversubscribed Seed funding for its novel Anti-Drug Conjugate (ADC) platforms, gearing up for Series A in H1 2024.